Is CRISPR Therapeutics stock going to $0, or will the hype pay off?

The past few years have been challenging for the biotech.

Eli Lilly is partnering with gene-editing start-up Seamless Therapeutics. Here's what investors need to know.

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?
Insider Monkey

9 Best Gene-Editing Stocks to Buy According to Hedge Funds

In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds. Genetic manipulation – or gene editing – is a concept that describes altering the genetic ...

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes ...

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026

Another place to seek out potentially explosive stocks is in the biotech space. These innovators are working on the ...
MarketWatch

Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...
Nasdaq

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam Therapeutics is one of the few biotechs that has shown immense potential in the gene therapy space. The company’s proprietary base-editing technology potentially enables the development of a ...
Insider Monkey

9 Best Gene-Editing Stocks to Buy According to Hedge Funds

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...